eMed Technologies will refile IPO

Article

Teleradiology and miniPACS provider eMed Technologies (formerly Access Radiology) has decided that the stock market is being friendlier to Internet and healthcare companies and plans to refile its initial public offering with the Securities and Exchange

Teleradiology and miniPACS provider eMed Technologies (formerly Access Radiology) has decided that the stock market is being friendlier to Internet and healthcare companies and plans to refile its initial public offering with the Securities and Exchange Commission. The Lexington, MA-based company pulled its IPO in November just as it was preparing to issue, citing a volatile market and investor apprehension about healthcare information systems vendors (SCAN 10/27/99).

eMed had hoped to raise more than $57 million through the IPO by selling 3.1 million shares at $12 to $14/share. The company anticipates the new IPO will be issued sometime during the first quarter of 2000, according to John Strauss, vice president of marketing. eMed also plans to use a different underwriter for this offering.

eMed is actively pursuing an Internet-based strategy that includes a new Web service for radiologists (eMed.net), and an extended relationship with compression software developer Aware to develop and market Web-based imaging products.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.